CS Medica Valuation

Is CSMED undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CSMED when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CSMED's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CSMED's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CSMED?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for CSMED. This is calculated by dividing CSMED's market cap by their current preferred multiple.
What is CSMED's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	DKK 55.91m

CSMED key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	14.6x
Enterprise Value/EBITDA	-4.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does CSMED's PS Ratio compare to its peers?

The above table shows the PS ratio for CSMED vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	12.6x
PMED PEPTONIC medical	2.3x	n/a	SEK 92.1m
ACUC AcuCort	15.9x	n/a	SEK 110.8m
CLBIO Corline Biomedical	6x	86.8%	SEK 171.9m
DBP B Double Bond Pharmaceutical International	26.2x	n/a	SEK 31.5m
CSMED CS Medica	18.7x	n/a	DKK 55.9m

Price-To-Sales vs Peers: CSMED is expensive based on its Price-To-Sales Ratio (18.7x) compared to the peer average (12.6x).

Price to Earnings Ratio vs Industry

How does CSMED's PE Ratio compare vs other companies in the SE Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	69.9%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	69.9%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: CSMED is expensive based on its Price-To-Sales Ratio (18.7x) compared to the Swedish Pharmaceuticals industry average (16x).

Price to Sales Ratio vs Fair Ratio

What is CSMED's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CSMED PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	18.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CSMED's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.